ClinicalTrials.gg
RecruitingNCT07115862Updated Nov 18, 2026

Effects of Pomegranate Juice on Ulcerative Colitis

An interventional study of pomegranate juice -> habitual diet and habitual diet -> pomegranate juice in Ulcerative Colitis (Disorder), sponsored by University of California, Los Angeles. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 615 studies in Colitis, Ulcerative with a site in United States — 115 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Planned enrollment
354th of 499
30 · median 76
Started
2025
with 37 others
No phase
103 of 615
25 open now
Primary completion
2027-10
later than 93 of 165 live
Registered
566th of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 354th largest by planned enrollment of the 499 interventional ones that give a count, is one of 38 that started in 2025, is one of 103 with no phase, reaches primary completion later than 93 of the 165 other live ones, and was the 566th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

115 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether consumption of 237 ml of pomegranate juice daily for 8 weeks will:

  1. lower inflammation (in the gut as well as generally in the body) and improve your overall quality of life
  2. affect the microbes living in the gut (gut microbiota)
Read the detailed description

the study is aimed at evaluating the effects of pomegranate juice (PomJ) on: 1) gut inflammation (fecal calprotectin and Simple Clinical Colitis Activity Index) and quality of life; 2) circulating inflammatory markers (e.g., hs-CRP, IL-6, IL-10, TNF-a, IL-1b, IL-8, LBP, LPS) and markers of oxidative stress (blood and urine malondialdehyde (MDA)) and 3) gut microbiota composition and functionality (urinary and circulating urolithin metabolites, fecal SCFAs/BAs, blood LBP and LPS, etc.). We will perform a randomized, controlled, 16-week trial to generate preliminary evidence on the effects of PomJ consumption in patients with mild-to-moderate UC. Participants will be randomly assigned to one of two groups: intervention group and delayed start group. The study will involve 2 phases, each lasting for 8 weeks. During Phase 1, the intervention group will consume 237 ml of PomJ daily, while the delayed start group will follow their habitual diet. Data generated from the delayed start group during Phase 1 will serve as the control for the study. During Phase 2, the intervention group will stop consuming PomJ and switch to consuming their habitual diet, while the delayed start group will consume 237 ml of PomJ daily for 8 weeks. Data generated from the intervention group during Phase 2 will serve as a follow-up to explore whether the effects of PomJ consumption persist after consumption is stopped (this will be an exploratory outcome).

03

Conditions studied

  • Ulcerative Colitis (Disorder)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Adults ≥ 18 yo

      • Following a low-polyphenol and fiber diet (\< 3 servings of fruits/vegetables per day)
      • Mild-to-moderate UC at the time of screening (2 ≤ partial Mayo scores ≤ 5)
      • Supportive evidence of active inflammation (hsCRP >1 mg/L, fecal calprotectin >50 µg/g stool, or abnormal lower endoscopy) in individuals with -proven UC
      • Patients on 5-aminosalicylates must be on a stable dose for ≥ 4 weeks prior to screening
      • Patients on treatment with therapy (e.g., azathioprine/6-mercaptopurine, methotrexate) must be on stable dose for 8 weeks prior to baseline visit
      • At the time of baseline visit, patients may be on no more than 20 mg/day of prednisone and 9 mg/day of budesonide MMX
      • Subjects must read and sign the Institutional Review Board-approved written prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.

Exclusion criteria

Exclusion Criteria:

    • Non-English speaker

      • Vegetarian/vegan
      • Known pomegranate allergy
      • Documented chronic disease besides UC, including diabetes, renal or liver diseases, metabolic syndrome, active cancer, MI or stroke, history of gastric bypass
      • Patients with CD, indeterminate/severe to fulminant colitis
      • History of colectomy or colonic dysplasia
      • Presence of ileal pouch or ostomy
      • Evidence of active bacterial or viral gastroenteritis as indicated by positive stool studies for ova \& parasites, Clostridium difficile, and stool culture
      • Recent hospitalizations (within 2 weeks of screening) for UC requiring IV
      • Presence of the following labs indicative of severe colitis: a. \< 8.0 g/dl b. Albumin \< 3.0 g/dl
      • Recent systemic antibiotics use (within 3 months of screening) or active use of anti-diarrheal medications
      • Taking supplements known to affect metabolism or gut microbiota composition (probiotics, fiber, etc.), unless willing to stop for the study duration
      • Use of Total Parenteral Nutrition (TPN)
      • Use of cyclosporine, tacrolimus, or thalidomide within 2 months prior to screening
      • Taking exogenous hormones (e.g., hormone replacement therapy)
      • Recent weight fluctuations (>10% in the last 6 months)
      • Smoker or living with a smoker
      • Use of >20 g of alcohol per day
      • Unable or unwilling to comply with the study protocol (including unwillingness to avoid watermelon and other lycopene-rich foods for the whole duration of the study)
      • Unable to provide consent
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants in this arm will be consuming 237 ml of pomegranate juice for the first 8 weeks of the study and their habitual diet without pomegranate juice for the second 8 weeks

    Other: pomegranate juice -> habitual diet

  • Experimental
    Delayed start

    Participants in this arm will consume their habitual diet for the first 8 weeks of the study and drink 237 ml of pomegranate juice for the second 8 weeks

    Other: habitual diet -> pomegranate juice

Interventions

  • Otherpomegranate juice -> habitual diet

    237 ml of pomegranate juice for the first 8 weeks -\> habitual diet for the second 8 weeks

  • Otherhabitual diet -> pomegranate juice

    habitual diet for the first 8 weeks -\> 237 ml of pomegranate juice for the second 8 weeks

06

What researchers measure

Primary outcomes

  1. simple clinical colitis activity index (SCCAI)

    Simple Clinical Colitis Activity Index (SCCAI) includes questions about bowel frequency, urgency of defecation, etc. Measured by the number of points/scores.

    Time frame: At baseline, 8 weeks and 16 weeks

  2. Fecal calprotectin

    To evaluate effects of PomJ on gut inflammation in patients with mild-to-moderate UC. The primary outcome will be levels of fecal calprotectin (objective measure). Fecal calprotectin levels will be assessed via a commercially available ELISA kit in mcg/g.

    Time frame: At baseline, 8 weeks and 16 weeks

Secondary outcomes

  1. Biomarkers of inflammation and oxidative stress

    Blood interleukin-6 (IL-6) in pg/ml

    Time frame: At baseline, week 8 and week 16

  2. Biomarkers of inflammation and oxidative stress

    Blood interleukin-10 (IL-10) in pg/ml

    Time frame: At baseline, week 8 and week 16

  3. Biomarkers of aging and oxidative stress

    Blood TNF-a in pg/ml

    Time frame: At baseline, week 8 and week 16

  4. Biomarkers of inflammation and oxidative stress

    Blood IL-1b in pg/ml

    Time frame: At baseline, week 8 and 16

  5. Biomarkers of inflammation and oxidative stress

    Blood IL-8 in pg/ml

    Time frame: At baseline, weeks 8 and 16

  6. Biomarkers of inflammation and oxidative stress

    Blood hs-CRP in mg/ml

    Time frame: At Baseline, weeks 8 and 16

  7. Biomarkers of inflammation and oxidative stress

    Urine malondialdehyde (MDA) in ng/ml

    Time frame: At baseline, weeks 8 and 16

  8. Biomarkers of inflammation and oxidative stress

    Blood MDA in nmol/ml

    Time frame: At baseline, weeks 8 and 16

  9. Biomarkers of inflammation and oxidative stress

    Urine 8OHdG in ng/mg

    Time frame: At baseline, weeks 8 and 16

  10. Biomarkers of inflammation and oxidative stress

    Blood 8OHdG in ng/ml

    Time frame: At baseline, weeks 8 and 16

Other outcomes

  1. Gut-derived metabolites

    Blood urolithin metabolites in micromoles/L

    Time frame: At baseline, weeks 8 and 16

  2. Gut-derived metabolites

    Urine urolithin metabolites

    Time frame: At baseline, weeks 8 and 16

  3. Microbial inflammatory components

    Blood lipopolysaccharide in ng/ml

    Time frame: At baseline, weeks 8 and 16

  4. Microbial inflammatory components

    Blood LPS binding protein in micrograms/ml

    Time frame: At baseline, weeks 8 and 16

  5. Microbial-derived metabolites

    Fecal short-chain fatty acids (SCFAs) in micromoles/g

    Time frame: At baseline, weeks 8 and 16

  6. Microbial-derived metabolites

    Fecal bile acids (BAs) in ng/ml

    Time frame: At baseline, weeks 8 and 16

  7. Gut microbiota composition

    The stool specimen will be collected by the participants at home at baseline and week 12 utilizing our Stool Collection Kit as per instructions. Immediately after collection, the specimen will be frozen in a home freezer and delivered in an insulated container to the UCLA Center for Human Nutrition. At UCLA, the specimen will be stored at - 80 ºC. Fecal microbiological analyses. Approximately 1g of the stool will be weighed and dried in a vacuum drying oven (15 in Hg) at 80 ºC for 48 hours, then weighed again to establish the moisture content so that all counts can be corrected to dry weight. From another aliquot of remaining fecal samples, DNA will be extracted using bead beating with a commercial extraction system (DNeasy PowerSoil® DNA Isolation Kit, Qiagen, Valencia, CA). The quality of the DNA samples will be confirmed using a Nanodrop 1000 (Thermo Fisher Scientific, Wilmington, DE). Extracted DNA will be transferred to UCLA Microbiome Core facility for MiSeq sequencing.

    Time frame: At baseline, weeks 8 and 16

07

Study locations

1 of 2 sites recruiting
  • West Los Angeles VA Medical Center
    Los Angeles, California 90073, United States
    Not yet recruiting
    • Tatiana Diacova, PhD, MS, RD · Contacttdiacova@mednet.ucla.edu · 310-206-8292
    • Zhaoping Li, MD, PhD · Principal investigator
  • UCLA Center for Human Nutrition
    Los Angeles, California 90095, United States
    Recruiting
    • Tatiana Diacova, PhD, MS, RD · Contacttdiacova@mednet.ucla.edu · 310-206-8292
    • Zhaoping Li, MD, PhD · Principal investigator
    • Berkeley Limketkai, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Data analysis will be performed in-house.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 228 non-industry interventional studies with no phase under Colitis, Ulcerative, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 24 months is below that.

Counting every sponsor, half of 239 studies reached it within 34 months; a quarter within 15 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 11, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Oct 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07115862
Responsible party
Zhaoping Li (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Aug 11, 2025
Start date
Oct 15, 2025
Primary completion
Oct 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Tatiana Diacova, PhD, MS, RDN
Contact
tdiacova@mednet.ucla.edu
310-206-8292
Zhaoping Li, MD, PhD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion